{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:11:59Z","timestamp":1794622319448,"version":"4.9.1"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>We evaluated outcomes of unrelated transplantation for primary refractory\/relapsed (ref\/rel) acute myeloid leukemia (AML), comparing two cohorts according to the year of transplant, 2000\u20132009 and 2010\u20132019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Multivariable analyses were performed using the Cox proportional-hazards regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>3,430 patients were included; 876 underwent a transplant between 2000\u20132009 and 2554 in 2010\u20132019. Median follow-up was 8.7 (95% CI, 7.8\u20139.4) and 3.4 (95% CI, 3.1\u20133.6) years (P &amp;lt; 0.001). Median age was 52 (18\u201377) and 56 (18\u201379) years (P &amp;gt; 0.0001); 45.5% and 55.5% had refractory AML while 54.5% and 44.5% had relapsed AML. Conditioning was myeloablative in 60% and 52%, respectively. Neutrophil recovery and day 100 incidence of acute and 2-year incidence of chronic graft-versus-host disease (GvHD) were similar between the two periods. Two-year relapse incidence was higher for patients undergoing transplant in the 2000\u20132009 period versus those undergoing transplant in 2010\u20132019: 50.2% versus 45.1% (HR, 0.85; 95% CI, 0.74\u20130.97; P = 0. 002). Leukemia-free survival; overall survival; and GvHD-free, relapse-free survival were lower for the 2000\u20132009 period: 26% versus 32.1% (HR, 0.87; 95% CI, 0.78\u20130.97; P = 0.01), 32.1% versus 38.1% (HR, 0.86; 95% CI, 0.77\u20130.96; P = 0.01), and 21.5% versus 25.3% (HR, 0.89; 95% CI, 0.81\u20130.99; P = 0.03), respectively. Two-year nonrelapse mortality was not significantly different (23.8% vs. 23.7%; HR, 0.91; 95% CI, 0.76\u20131.11; P = 0.34).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Outcome of unrelated transplantation for patients with ref\/rel AML has improved in the last two decades, rescuing about one third of the patients.<\/jats:p>\n                    <jats:p>See related commentary by Adrianzen-Herrera and Shastri, p. 4167<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-22-0809","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T16:40:49Z","timestamp":1656348049000},"page":"4258-4266","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed\/Refractory Acute Myeloid Leukemia: An ALWP\/EBMT Analysis"],"prefix":"10.1158","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[{"name":"1Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-6900","authenticated-orcid":false,"given":"Maud","family":"Ngoya","sequence":"additional","affiliation":[{"name":"2EBMT Statistical Unit, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[{"name":"2EBMT Statistical Unit, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[{"name":"3Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France, Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-3029","authenticated-orcid":false,"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[{"name":"4Universitaetsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"5University of Muenster, Department of Hematology\/Oncology, Muenster, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5927","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[{"name":"6University of Freiburg, Department of Medicine-Hematology, Oncology, Freiburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[{"name":"7Hannover Medical School Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Einsele","sequence":"additional","affiliation":[{"name":"8Universitaetsklinikum Wuerzburg, Med. Klinik und Poliklinik II, Wuerzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"9University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Brecht","sequence":"additional","affiliation":[{"name":"10Deutsche Klinik fuer Diagnostik, KMT Zentrum, Wiesbaden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"11Universitaet Tuebingen, Medizinische Klinik, Tuebingen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Edinger","sequence":"additional","affiliation":[{"name":"12University Regensburg, Department of Hematology and Oncology, Regensburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"Aleksandr","family":"Kulagin","sequence":"additional","affiliation":[{"name":"13First State Pavlov Medical University of St. Petersburg, Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, St. Petersburg, Russia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"14University Hospital Hematology, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[{"name":"15Medizinische Klinik m. S. H\u00e4matologie, Onkologie und Tumorimmunologie, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Elmaagacli","sequence":"additional","affiliation":[{"name":"16Asklepios Klinik St. Georg, Department of Haematology, Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[{"name":"17Klinikum Nuernberg, 5. Medizinische Klinik, BMT-Unit, Nuernberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"18Medical Clinic and Policinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[{"name":"19University Hospital Department of Bone Marrow Transplantation, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Bunjes","sequence":"additional","affiliation":[{"name":"20Klinik fuer Innere Medzin III, Universit\u00e4tsklinikum Ulm, Ulm, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[{"name":"21Klinikum Grosshadern, Med. Klinik III, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-6834","authenticated-orcid":false,"given":"Sonja","family":"Martin","sequence":"additional","affiliation":[{"name":"22Robert_Bosch_Krankenhaus, Abt. H\u00e4matologie \/ Onkologie, Stuttgart, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[{"name":"23Department of Internal Medicine, BMT Unit, University Hospital of Patras, Patras, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[{"name":"24Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute-Oncology Center, Gliwice Branch, Gliwice, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[{"name":"25Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"3Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France, Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"2025112507184269400_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the american society of transplantation and cellular therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2025112507184269400_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112507184269400_bib3","doi-asserted-by":"crossref","first-page":"659595","DOI":"10.3389\/fimmu.2021.659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?","volume":"12","author":"Loke","year":"2021","journal-title":"Front Immunol"},{"key":"2025112507184269400_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"2025112507184269400_bib5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40\u2009000 transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2025112507184269400_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.beha.2012.10.009","article-title":"Improved outcomes with allogeneic hematopoietic cell transplantation","volume":"25","author":"Appelbaum","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025112507184269400_bib7","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s?. A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"key":"2025112507184269400_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/joim.12854","article-title":"Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP\/EBMT analysis","volume":"285","author":"Canaani","year":"2019","journal-title":"J Intern Med"},{"key":"2025112507184269400_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohort","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025112507184269400_bib10","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S2352-3026(20)30394-X","article-title":"Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the european society for blood and marrow transplantation registry","volume":"8","author":"Shouval","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025112507184269400_bib11","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","article-title":"Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis","volume":"2","author":"Nagler","year":"2015","journal-title":"Lancet Haematol"},{"key":"2025112507184269400_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stemcell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the acute leukemia working party of the EBMT","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"key":"2025112507184269400_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.26000","article-title":"The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT)","volume":"96","author":"Poiani","year":"2021","journal-title":"Am J Hematol"},{"key":"2025112507184269400_bib14","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","article-title":"Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years","volume":"26","author":"Bazarbachi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025112507184269400_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"2025112507184269400_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41409-020-01050-7","article-title":"Total body irradiation + fludarabine compared to busulfan + fludarabine as \"reduced-toxicity conditioning\" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT","volume":"56","author":"Giebel","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2025112507184269400_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","article-title":"Testing for center effects in multi-center survival studies: a monte carlo comparison of fixed and random effects tests","volume":"18","author":"Andersen","year":"1999","journal-title":"Stat Med"},{"key":"2025112507184269400_bib18","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2017"},{"key":"2025112507184269400_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"2025112507184269400_bib20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112507184269400_bib21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2025112507184269400_bib22","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Acute leukaemia working party of the European group for blood and marrow transplantation (EBMT). treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"2025112507184269400_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025112507184269400_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/leu.2011.13","article-title":"Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia","volume":"25","author":"Craddock","year":"2011","journal-title":"Leukemia"},{"key":"2025112507184269400_bib25","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025112507184269400_bib26","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/leu.2013.208","article-title":"The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo","volume":"27","author":"Todisco","year":"2013","journal-title":"Leukemia"},{"key":"2025112507184269400_bib27","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00277-021-04565-1","article-title":"Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two east german study group hematology and oncology (OSHO) trials","volume":"100","author":"Heinicke","year":"2021","journal-title":"Ann Hematol"},{"key":"2025112507184269400_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"2025112507184269400_bib29","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT acute leukemia working party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"key":"2025112507184269400_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025112507184269400_bib31","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease \u2014 biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"2025112507184269400_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.21873\/anticanres.11483","article-title":"Acute graft versus host disease: a comprehensive review","volume":"37","author":"Nassereddine","year":"2017","journal-title":"Anticancer Res"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-22-0809\/3164504\/ccr-22-0809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/28\/19\/4258\/3208950\/4258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/28\/19\/4258\/3208950\/4258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:18:53Z","timestamp":1764073133000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/28\/19\/4258\/709312\/Longitudinal-Outcome-over-Two-Decades-of-Unrelated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":32,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,6,7]]},"published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-0809","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.22489148","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22489145","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22489151","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.22489145.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22489151.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22489148.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6532892","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6532892.v1","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}